Vaxart Q3 net loss $29.3M; cash $114.8M; clinical milestones set for 2023

Vaxart, Inc.

Net loss $29.3M ($0.23 EPS) vs $17.6M ($0.14) Q3 2021; R&D spend rose 81% to $22.5M.
Cash & securities $114.8M at Sep 30, down from $131.5M at Jun 30; ops used $14.6M.
Phase II COVID-19 vaccine showed mucosal IgA and cross-reactivity to Omicron; UK challenge trial set for 2H 2023.
Norovirus Phase Ib in elderly (55-80) showed dose-dependent IgA; Phase II challenge data expected Q1/Q2 2023.
Added Ray Stapleton as CTO and Elaine Heron & Mark Watson to board in August 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vaxart, Inc. reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 8, 2022, Vaxart, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Vaxart, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-22-026356

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.